The downgrade from Buy to Hold by Canaccord Genuity indicates a less optimistic outlook for Zynerba Pharmaceuticals. The significant reduction in the price target from $10 to $1.11 suggests that the analyst sees limited upside potential for the stock, which could negatively impact its short-term price.